← Eichor
Study identifier: NCT06873321 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

VTE Incidence After Rivaroxaban + Aspirin or SAPT After Lower-limb Revascularization

Condition: Peripheral Arterial Disease · Venous Thormboembolism · Cardiovascular Diseases  ·  Sponsor: Science Valley Research Institute

PhasePhase 4
Planned participants100
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

Venous thromboembolism (VTE) has a high prevalence in patients with multiple comorbidities undergoing complex surgical procedures. Sometimes, extended prophylaxis for VTE with KLMWH or direct oral anticoagulants (DOACs) is necessary. Currently, there is no consensus in the literature regarding the use of DOACs for extended VTE prophylaxis in patients undergoing lower limb revascularization (LLR). Objective: To evaluate the use of DOACs (already approved to reduce MACE and MALE) in VTE prophylaxis in patients undergoing LLR.

This description comes directly from the study's public registry record.

Talk to the study team

Gabriela Oliveira Buril, MD  ·  +5581991121872  ·  gabriela.buril@ufpe.br

Always discuss trial participation with your own doctor first.

Locations (1)

Hospital das Clínicas, Federal University of PernambucoPernambuco, Pernambuco, BrazilRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06873321